CJC-1295 / Ipamorelin is a research peptide combination studied for its effects on growth hormone (GH) and IGF-1 signaling pathways. CJC-1295 acts on growth hormone-releasing hormone pathways, while Ipamorelin is a growth hormone secretagogue that acts at the ghrelin receptor.
Research interest includes:
Growth hormone release and regulation
IGF-1 signaling
Muscle and recovery pathways
Body-composition and metabolic research
Sleep and recovery mechanisms
Healthy-aging research
10 mg refers to the total amount of peptide in the vial; the exact CJC-1295-to-Ipamorelin ratio should be confirmed from the product label.
Important: CJC-1295 and Ipamorelin are not FDA-approved for human use, weight loss, muscle building, anti-aging, or other medical treatments. Human clinical evidence is limited.
